Proteomic analysis of plasma from a Tau transgenic mouse

International Journal of Developmental Neuroscience

Volumn 30, Issue 4, 2012, Pages 277-283

  Kim, Yoon Ha ^a   Lee, Eun Kyung ^a   Park, Seung Ah ^a   Kim, Nam Hee ^a   Kim, Chan Wha ^a  

^a Korea University   (South Korea)

Author keywords

2 Dimensional gel electrophoresis; Adenosine kinase; ATP synthase; Regucalcin; Tau transgenic mouse

Indexed keywords

ADENOSINE KINASE; BIOLOGICAL MARKER; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; REGUCALCIN; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; FEMALE; LIQUID CHROMATOGRAPHY; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TANDEM MASS SPECTROMETRY; TRANSGENIC MOUSE; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING;

ADENOSINE KINASE; AGE FACTORS; ANALYSIS OF VARIANCE; ANIMALS; ATP SYNTHETASE COMPLEXES; CALCIUM-BINDING PROTEINS; CHROMATOGRAPHY, LIQUID; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; GENE EXPRESSION REGULATION; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, TRANSGENIC; MUTATION; PLASMA; PROTEOMICS; SILVER STAINING; TANDEM MASS SPECTROMETRY; TAU PROTEINS;

MUS MUSCULUS;

EID: 84862826687     PISSN: 07365748     EISSN: 1873474X     Source Type: Journal    
DOI: 10.1016/j.ijdevneu.2012.01.011     Document Type: Article

References (48)

1. Baloyannis S.J. Mitochondrial alterations in Alzheimer's disease. J. Alzheimers Dis. 2006, 9:119-126.
2. Besga A., Ortiz L., Fernandez A., Maestu F., Arrazola J., Gil-Gregorio P., Fuentes M., Ortiz T. Structural and functional patterns in healthy aging, mild cognitive impairment, and alzheimer disease. Alzheimer Dis. Assoc. Disord. 2009.
3. Bidzan L., Pachalska M., Grochmal-Bach B., Bidzan M., Cieslukowska A., Pufal A. Behavioral and psychological symptoms in the preclinical stage of Alzheimer's disease. Med. Sci. Monit. 2008, 14:CR473-CR479.
4. Blennow K., de Leon M.J., Zetterberg H. Alzheimer's disease. Lancet 2006, 368:387-403.
5. Blennow K., Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol. 2003, 2:605-613.
6. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72:248-254.
7. Buerger K., Teipel S.J., Zinkowski R., Blennow K., Arai H., Engel R., Hofmann-Kiefer K., McCulloch C., Ptok U., Heun R., Andreasen N., DeBernardis J., Kerkman D., Moeller H., Davies P., Hampel H. CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology 2002, 59:627-629.
8. Chan D., Janssen J.C., Whitwell J.L., Watt H.C., Jenkins R., Frost C., Rossor M.N., Fox N.C. Change in rates of cerebral atrophy over time in early-onset Alzheimer's disease: longitudinal MRI study. Lancet 2003, 362:1121-1122.
9. Chen M., Inestrosa N.C., Ross G.S., Fernandez H.L. Platelets are the primary source of amyloid beta-peptide in human blood. Biochem. Biophys. Res. Commun. 1995, 213:96-103.
10. Clark C.M., Pratico D., Shaw L.M., Leight S., Xie S.X., Gu A., Lee V.M., Trojanowski J.Q. Commentary on Optimal design of clinical trials for drugs designed to slow the course of Alzheimers disease. Biochemical biomarkers of late-life dementia. Alzheimers Dement. 2006, 2:287-293.
11. Corder E.H., Saunders A.M., Risch N.J., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Rimmler J.B., Locke P.A., Conneally P.M., Schmader K.E., et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat. Genet. 1994, 7:180-184.
12. de Leon M.J., DeSanti S., Zinkowski R., Mehta P.D., Pratico D., Segal S., Rusinek H., Li J., Tsui W., Saint Louis L.A., Clark C.M., Tarshish C., Li Y., Lair L., Javier E., Rich K., Lesbre P., Mosconi L., Reisberg B., Sadowski M., DeBernadis J.F., Kerkman D.J., Hampel H., Wahlund L.O., Davies P. Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol. Aging 2006, 27:394-401.
13. DeKosky S.T. Pathology and pathways of Alzheimer's disease with an update on new developments in treatment. J. Am. Geriatr. Soc. 2003, 51:S314-S320.
14. DeKosky S.T., Marek K. Looking backward to move forward: early detection of neurodegenerative disorders. Science 2003, 302:830-834.
15. Desikan R.S., Cabral H.J., Hess C.P., Dillon W.P., Glastonbury C.M., Weiner M.W., Schmansky N.J., Greve D.N., Salat D.H., Buckner R.L., Fischl B. Automated MRI measures identify individuals with mild cognitive impairment and Alzheimer's disease. Brain 2009, 132:2048-2057.
16. Drzezga A. Diagnosis of Alzheimer's disease with [18F]PET in mild and asymptomatic stages. Behav. Neurol. 2009, 21:101-115.
17. Frank R.A., Galasko D., Hampel H., Hardy J., de Leon M.J., Mehta P.D., Rogers J., Siemers E., Trojanowski J.Q. Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. Neurobiol. Aging 2003, 24:521-553.
18. German D.C., Gurnani P., Nandi A., Garner H.R., Fisher W., Diaz-Arrastia R., O'Suilleabhain P., Rosenblatt K.P. Serum biomarkers for Alzheimer's disease: proteomic discovery. Biomed. Pharmacother. 2007, 61:383-389.
19. Hansson O., Zetterberg H., Buchhave P., Londos E., Blennow K., Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006, 5:228-234.
20. Hye A., Lynham S., Thambisetty M., Causevic M., Campbell J., Byers H.L., Hooper C., Rijsdijk F., Tabrizi S.J., Banner S., Shaw C.E., Foy C., Poppe M., Archer N., Hamilton G., Powell J., Brown R.G., Sham P., Ward M., Lovestone S. Proteome-based plasma biomarkers for Alzheimer's disease. Brain 2006, 129:3042-3050.
21. Izumi T., Yamaguchi M. Overexpression of regucalcin suppresses cell death and apoptosis in cloned rat hepatoma H4-II-E cells induced by lipopolysaccharide, PD 98059, dibucaine, or Bay K 8644. J. Cell. Biochem. 2004, 93:598-608.
22. Jack C.R., Shiung M.M., Weigand S.D., O'Brien P.C., Gunter J.L., Boeve B.F., Knopman D.S., Smith G.E., Ivnik R.J., Tangalos E.G., Petersen R.C. Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. Neurology 2005, 65:1227-1231.
23. Kim H.J., Cho E.H., Yoo J.H., Kim P.K., Shin J.S., Kim M.R., Kim C.W. Proteome analysis of serum from type 2 diabetics with nephropathy. J. Proteome Res. 2007, 6:735-743.
24. Kim J.S., Kim E.J., Kim H.J., Yang J.Y., Hwang G.S., Kim C.W. Proteomic and metabolomic analysis of H(2)O(2)-induced premature senescent human mesenchymal stem cells. Exp. Gerontol. 2011.
25. Kim J.S., Lee H.K., Kim M.R., Kim P.K., Kim C.W. Differentially expressed proteins of mesenchymal stem cells derived from human cord blood (hUCB) during osteogenic differentiation. Biosci. Biotechnol. Biochem. 2008, 72:2309-2317.
26. Kulkarni J.S., Przywara D.A., Wakade T.D., Wakade A.R. Adenosine induces apoptosis by inhibiting mRNA and protein synthesis in chick embryonic sympathetic neurons. Neurosci. Lett. 1998, 248:187-190.
27. Lee E.K., Han G.Y., Park H.W., Song Y.J., Kim C.W. Transgelin promotes migration and invasion of cancer stem cells. J. Proteome Res. 2010, 9:5108-5117.
28. Mehta P.D., Pirttila T., Patrick B.A., Barshatzky M., Mehta S.P. Amyloid beta protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease. Neurosci. Lett. 2001, 304:102-106.
29. Misawa H., Inagaki S., Yamaguchi M. Suppression of cell proliferation and deoxyribonucleic acid synthesis in the cloned rat hepatoma H4-II-E cells overexpressing regucalcin. J. Cell. Biochem. 2001, 84:143-149.
30. Morris J.C., Price A.L. Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. J. Mol. Neurosci. 2001, 17:101-118.
31. Nakagawa T., Yamaguchi M. Overexpression of regucalcin suppresses cell response for tumor necrosis factor-alpha or transforming growth factor-beta1 in cloned normal rat kidney proximal tubular epithelial NRK52E cells. J. Cell. Biochem. 2007, 100:1178-1190.
32. Neugroschl J., Sano M. An update on treatment and prevention strategies for Alzheimer's disease. Curr. Neurol. Neurosci. Rep. 2009, 9:368-376.
33. Park S.A., Park H.W., Kim N.H., Kim Y.H., Kwak M.J., Shin J.S., Kim C.W. Effects of Tau on the activity of triose phosphate isomerase (TPI) in brain cells. Neurochem. Int. 2010, 56:886-892.
34. Price J.L., McKeel D.W., Buckles V.D., Roe C.M., Xiong C., Grundman M., Hansen L.A., Petersen R.C., Parisi J.E., Dickson D.W., Smith C.D., Davis D.G., Schmitt F.A., Markesbery W.R., Kaye J., Kurlan R., Hulette C., Kurland B.F., Higdon R., Kukull W., Morris J.C. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol. Aging 2009, 30:1026-1036.
35. Ridha B.H., Barnes J., Bartlett J.W., Godbolt A., Pepple T., Rossor M.N., Fox N.C. Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study. Lancet Neurol. 2006, 5:828-834.
36. Ringman J.M., Medina L.D., Rodriguez-Agudelo Y., Chavez M., Lu P., Cummings J.L. Current concepts of mild cognitive impairment and their applicability to persons at-risk for familial Alzheimer's disease. Curr. Alzheimer Res. 2009, 6:341-346.
37. Shim S.B., Lim H.J., Chae K.R., Kim C.K., Hwang D.Y., Jee S.W., Lee S.H., Sin J.S., Leem Y.H., Cho J.S., Lee H.H., Choi S.Y., Kim Y.K. Tau overexpression in transgenic mice induces glycogen synthase kinase 3beta and beta-catenin phosphorylation. Neuroscience 2007, 146:730-740.
38. Silbert L.C., Quinn J.F., Moore M.M., Corbridge E., Ball M.J., Murdoch G., Sexton G., Kaye J.A. Changes in premorbid brain volume predict Alzheimer's disease pathology. Neurology 2003, 61:487-492.
39. Silverman D.H., Small G.W., Chang C.Y., Lu C.S., Kung De Aburto M.A., Chen W., Czernin J., Rapoport S.I., Pietrini P., Alexander G.E., Schapiro M.B., Jagust W.J., Hoffman J.M., Welsh-Bohmer K.A., Alavi A., Clark C.M., Salmon E., de Leon M.J., Mielke R., Cummings J.L., Kowell A.P., Gambhir S.S., Hoh C.K., Phelps M.E. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA 2001, 286:2120-2127.
40. Singh B., Hao W., Wu Z., Eigl B., Gupta R.S. Cloning and characterization of cDNA for adenosine kinase from mammalian (Chinese hamster, mouse, human and rat) species. High frequency mutants of Chinese hamster ovary cells involve structural alterations in the gene. Eur. J. Biochem. 1996, 241:564-571.
41. Spychala J., Datta N.S., Takabayashi K., Datta M., Fox I.H., Gribbin T., Mitchell B.S. Cloning of human adenosine kinase cDNA: sequence similarity to microbial ribokinases and fructokinases. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:1232-1237.
42. Steenland K., MacNeil J., Vega I., Levey A. Recent trends in Alzheimer disease mortality in the United States, 1999 to 2004. Alzheimer Dis. Assoc. Disord. 2009, 23:165-170.
43. Sunderland T., Gur R.E., Arnold S.E. The use of biomarkers in the elderly: current and future challenges. Biol. Psychiatry 2005, 58:272-276.
44. Sunderland T., Linker G., Mirza N., Putnam K.T., Friedman D.L., Kimmel L.H., Bergeson J., Manetti G.J., Zimmermann M., Tang B., Bartko J.J., Cohen R.M. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 2003, 289:2094-2103.
45. Thal L.J., Kantarci K., Reiman E.M., Klunk W.E., Weiner M.W., Zetterberg H., Galasko D., Pratico D., Griffin S., Schenk D., Siemers E. The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis. Assoc. Disord. 2006, 20:6-15.
46. Yamaguchi M. Role of regucalcin in calcium signaling. Life Sci. 2000, 66:1769-1780.
47. Yamaguchi M. The role of regucalcin in nuclear regulation of regenerating liver. Biochem. Biophys. Res. Commun. 2000, 276:1-6.
48. Yamaguchi M. Role of regucalcin in maintaining cell homeostasis and function (review). Int. J. Mol. Med. 2005, 15:371-389.